Ranier’s Compounding Laboratory, Jeannette, PA

Is Ranier’s Compounding Laboratory registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Ranier’s Compounding Laboratory hold a Pennsylvania pharmacy license?

State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.

Has Ranier’s Compounding Laboratory had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 2 Form 483s (Aug 16, 2021 and Feb 13, 2024) for Ranier’s Compounding Laboratory. State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Ranier’s Compounding Laboratory
Location
Jeannette, PA
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
0
Latest action on that page
Feb 13, 2024
FDA Data Dashboard inspections
4 inspections: 2 OAI, 2 VAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 10 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Ranier’s Compounding Laboratory, a 503A facility, with 3 dated actions.

Document
Feb 13, 2024Form 483483 Issued 02/13/2024FDA copy (archived)
Aug 16, 2021Form 483483 Issued 08/16/2021FDA copy (archived)
Feb 6, 2019Press release or statementFDA Press Release : Federal Court Enters Consent Decree Against Ranier's Rx Laboratory and Owner for Manufacturing Purportedly Sterile Drug Products in Unsanitary Conditions (02/06/2019)FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Ranier's Compounding Laboratory, Jeannette, PA (FEI number 3012124170), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Feb 13, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI)30121241701229601
Aug 16, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30121241701148893
May 22, 2018Official Action Indicated (OAI)Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI); Drug Quality Assurance (Drugs): Official Action Indicated (OAI)30121241701052807
Apr 22, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3012124170975474

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 10 numbered observations in all, across 3 inspections ending Apr 22, 2016 to Feb 13, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 5, 2024 to Feb 13, 2024: 2 observations

Firm on the cover
Rainier's Compounding Laboratory, 1107 Lowry Ave, Jeannette, PA 15644-3030
FEI number
3012124170
Establishment type on the cover
Producer of Non-Sterile Drug Products
FDA district office on the cover
US Customhouse Rm 900 200 Chestnut St Philadelphia, PA 19106
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Vermin or other animals or evidence of their presence was observed in the production area.

Specifically, on 02/05/2024, I observed three ceiling lights in your general compounding lab area that contained one to two apparent dead insects. Examples of non-sterile products being made during the inspection on 02/05/2024 includes the following:

Drug Name form Expiration Date uOt Number Enalanril l MG/O.25 ML. Susnension 08/03/2024 020524-4 Pimobendan O.5MG/O.25 ML. Susnension 04/03/2024 020524-3 Furosemide VET CMPD l OMG/ML. Susnension 08/03/2024 020524-6 Guanfacine l MG/ML. Susnension 02/19/2024 020524-2

Repeat Observation from 2021 FDA 483.

Observation 2

Use of ingredients not intended for pharmaceutical use in non-sterile drug production.

Specifically, you failed to purchase and use the appropriate compendia} grade components when preparing and producing human and veterinary drug products. A store brand ingredient, [ (b)(4)j was used in the preparation of Lidocaine/ Prilocaine/ Tetracaine/ Phenylephrine 12.5/2/12.5/3% Dental Paste, Lot 113023-1, Beyond Use Date: 01/30/2024, and Lot 091823-1, Beyond Use Date: 10/18/2023. Both products were distributed to the patients for use.

Inspection Aug 4, 2021 to Aug 16, 2021: 1 observation

Firm on the cover
Ranier's Rx Laboratory, Inc., 1107 Lowry Ave., Jeannette,, PA 15644-3030
FEI number
3012124170
Establishment type on the cover
Non-sterile Drug Manufacturer
FDA district office on the cover
US Custom House Rm 900 200 Chestnut St. Philadelphia, PA 19106 Phone: {216) 597-4390 ext. 4200
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Vermin was observed in your production area.

Speciflcally, on 08/06/2021, I observed six ceiling lights In your general compounding lab area and one ceiling light In the hallway to your hazardous compounding room to contain two to 12 apparent dead insects. furthermore, I observed a cracked ceiling light that sits approximately 24 inches directly above hood <Redacted B4> in your general compounding lab and approximately an 0.25-inch gap in the ceiling light within your hazardous compounding room. Examples of non sterile product being made during the inspection on 08/06/2021 Includes the following:

Drug Name, form

Expiration Date

Lot Number

Aluminum Hydroxide 135mg/mL, suspension 08/20/2021 080621-7

ABH 0.5/20/0.5 mg/1 ml, gel

Biest (80:20)/Testosterone0.5/1mg/ml, cream

BMX Mouthwash l: I: I. suspension

Guanfacine l mg/ml suspension

Progesterone (veg capsules) 100mg capsules 02/02/2022

Vancomycin 250mg/5ml, solution 08/20/2021

Gabapentin 10mg/ml (VET), suspension 10/01/2021

Inspection Apr 18, 2016 to Apr 22, 2016: 7 observations

Firm on the cover
Ranier ' s Compounding Laborat ory, 1107 Lowry Ave Ste A, Jeannette, PA 15644-3030
FEI number
3012124170
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
US Customhouse Rm900 2nd & Chestnut St, Philadelphia, PA 19106,
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

1. Technicians were observed not practicing good aseptic technique while performing aseptic manipulations in the ISO 5 critical area. For example,

a. On multiple occasions technicians were observed donning sterile gloves inside the ISO 5 hood immediately prior to prior to beginning aseptic processing.

b. On 4/18/16, during the production of Amphotericin B Liposome 25mg /6ml Inhalation Solution the technician was observed vigorously shaking product after addition of a REDACTED B4 to aid in dissolution of lyophilized powder with the gloved index finger covering the stopper. This process was REDACTED B4 of finished product. No additional sterilization method was observed or documented. Additionally, components were staged in manner requiring the technician to extend arms and upper torso over the stoppered vials.

c. Technicians were observed introducing nonsterile components and equipment into the ISO 5 critical zone

without disinfecting. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

1. REDACTED B4 are not used to verify the sterilization REDACTED B4 to sterilize Medroxyprogesterone Ophthalmic Suspension 1%.

2. The effectiveness of the REDACTED B4 sterilization REDACTED B4 sterilize glassware REDACTED B4 use in sterile operations has not been verified through the performance of an endotoxin challenge.

3. REDACTED B4 is not performed on REDACTED B4 used in the sterile REDACTED B4 of drug product.

4. There is no evidence that media fills are performed under the most stressful or challenging

conditions. The Media-Fill Test Procedure for CSPs Sterilized by REDACTED B4 provided lacks sufficient detail with respect to technician instruction and materials, components and equipment used

in the process.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

1. Environmental monitoring of surfaces for microbial contamination is not performed on a daily basis after the completion of sterile operations in the ISO 5 area. Your firm only performs such monitoring on a REDACTED B4 basis. Additionally, it was reported that the ISO 5 critical area is wiped with sterile REDACTED B4.

2. Technician's gloves are not monitored for microbial contamination after the completion of sterile operations. Glove tips are monitored on a REDACTED B4 basis. Additionally, it was reported by that the REDACTED B4 is only sampled.

3. Environmental monitoring for non-viable particulates and viable air counts is not performed on a daily basis during routine sterile operations. Such monitoring is performed on a REDACTED B4 b asis REDACTED B4.

4. Pressure gauges in the ISO 5 Hood and the ISO 7 Ante Room are not continuously monitored for air pressure differential. Instead personnel perform a REDACTED B4 of the pressure reading and make a record on the Pressure Gauge Log. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

1. The firm does not use a sporicidal agent to disinfect the clean room including the ISO 5 area. REDACTED B4 cleaning of the ISO 5 critical areas consists of Sterile REDACTED B4.

2. On 4/17/16, a spray bottle label REDACTED B4 in the clean room. The firm replied that the spray bottle contains REDACTED B4 used during sterile operations in the ISO 5 area. The spray bottle is non-sterile but sanitized using sterile REDACTED B4 prior to the addition of REDACTED B4. On 4/20/16, the spray bottle was observed inside the ISO 5 critical area being used by the technician to wet a non-sterile towel to wipe residue from the pH meter during the compounding of Lipoic Acid 25mg/ml INJ Solution (batch 41915-2CR).

4. Non-sterile lint free wipes are used by the firm to clean and disinfect the ISO 5 hood.

3. White spotty residue was observed on the ISO 5 aseptic hood REDACTED B4.

Observation 5

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically,

Gowns/coveralls, facemasks and bouffant hair nets worn by operators working inside ISO 5 zones are not sterile. Additionally, the technician's face and neck are not fully covered allowing exposed facial skin and hair over the ISO 5 critical area.

Observation 6

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

Finished product is not tested for sterility and/or endotoxin. According to the firm, sterility and/or endotoxin testing is only performed REDACTED B4. For example,

1. Lipoic Acid 25mg/ml INJ Solution (batch # 041916-2CR) beyond use date of 5/19/16 (30 days) was dispensed without sterility and/or endotoxin testing.

2. Hydrochloric Acid 2.0mg/ml preservative free INJ Solution (batch# 030915-6CR) beyond use date of 4/18/16 (30 days) was dispensed without sterility and/or endotoxin testing.

Observation 7

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

No studies have been conducted to evaluate the characteristics of drug product for the beyond use dates

assigned. For example,

1. Lipoic Acid 25mg/rnl INJ Solution (batch # 041916-2CR) beyond use date of 5/19/ 16 (30 days).

DATE ISSU!OD

2. Hydrochloric Acid 2.0mg/ml preservative free INJ Solution (batch# 030915-6CR) beyond use date of 4/18/16 (30 days)

3. Thiamine HC1100mg/ml Injectable (batch# 032916-4CR)) beyond use date of 6/27/16 (90 days).

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.